Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A method of reducing breast density, comprising percutaneously administering, to a patient having class III or class IV dense breast composition, a pharmaceutical composition for percutaneous administration comprising 4-hydroxy tamoxifen and isopropyl myristate.

2. (Original) A method according to claim 1, wherein said dense breast tissue is diffuse.

3. (Original) A method according to claim 1, wherein said dense breast tissue is nodular.

4. (Canceled)

5. (Previously Presented) A method according to claim 1, wherein said 4-hydroxy tamoxifen is a blend of *trans* and *cis* isomers.

6. (Original) A method according to claim 1, wherein said 4-hydroxy tamoxifen is a *trans* isomer.

7. (Original) A method according to claim 1, wherein greater than about 0.5 mg/breast of said 4-hydroxy tamoxifen is administered per day.

8. (Original) A method according to claim 1, wherein greater than about 0.75 mg/breast of said 4-hydroxy tamoxifen is administered per day.

9. (Original) A method according to claim 1, wherein greater than about 1.0 mg/breast of said 4-hydroxy tamoxifen is administered per day.

10. (Previously Presented) A method according to claim 1, wherein said pharmaceutical composition comprises a hydroalcoholic gel.

11. (Original) A method according to claim 10, wherein said hydroalcoholic gel comprises ethyl alcohol, isopropyl myristate, and hydroxypropylcellulose.

12. (Previously Presented) A method according to claim 1, wherein said pharmaceutical composition comprises an alcoholic solution.

13. (Previously Presented) A method of improving mammographic sensitivity that comprises performing the method of claim 1, then performing mammography on said patient.

14. (Canceled)

15. (Currently Amended) A method according to claim 13, wherein said 4-hydroxy tamoxifen is a ~~racemic~~ blend of *trans* and *cis* isomers.

16. (Previously Presented) A method according to claim 13, wherein said 4-hydroxy tamoxifen is a *trans* isomer.

17. (Previously Presented) A method according to claim 13, wherein greater than about 0.5 mg/breast of said 4-hydroxy tamoxifen has been administered per day.

18. (Previously Presented) A method according to claim 13, wherein greater than about 0.75 mg/breast of said 4-hydroxy tamoxifen has been administered per day.

19. (Previously Presented) A method according to claim 13, wherein greater than about 1.0 mg/breast of said 4-hydroxy tamoxifen has been administered per day.

20. (Previously Presented) A method according to claim 13, wherein said pharmaceutical composition comprises a hydroalcoholic gel.

21. (Previously Presented) A method according to claim 20, wherein said hydroalcoholic gel comprises ethyl alcohol, isopropyl myristate, and hydroxypropylcellulose.

22. (Canceled)

23. (Previously Presented) A method according to claim 10, wherein said pharmaceutical composition comprises 4-hydroxy tamoxifen, ethyl alcohol, isopropyl myristate, hydroxypropylcellulose and phosphate buffer.

24. (Previously Presented) A method according to claim 10, wherein said pharmaceutical composition comprises from about 0.001 g to about 1.0 g of 4-hydroxy tamoxifen per 100 g gel.

25. (Previously Presented) A method according to claim 24, wherein said pharmaceutical composition comprises from about 0.01 g to about 0.1 g of 4-hydroxy tamoxifen per 100 g gel.

26. (Previously Presented) A method according to claim 20, wherein said pharmaceutical composition comprises 4-hydroxy tamoxifen, ethyl alcohol, isopropyl myristate, hydroxypropylcellulose and phosphate buffer.

27. (Previously Presented) A method according to claim 20, wherein said pharmaceutical composition comprises from about 0.001 g to about 1.0 g of 4-hydroxy tamoxifen per 100 g gel.

28. (Previously Presented) A method according to claim 27, wherein said pharmaceutical composition comprises from about 0.01 g to about 0.1 g of 4-hydroxy tamoxifen per 100 g gel.